IP Library Granted Patent US 10,428,307
Granted Patent B2
US 10,428,307 · App. 15/570,619 · Granted Oct 1, 2019

Method for converting mesenchymal stem cells into endothelial cells by using specific transcription factors

Inventor: Young-Ae Joe (Seoul, KR)
Assignee: The Catholic University of Korea Industry-Academic Cooperation Foundation
C12N5/0665C12N5/069C12N5/0668C12N15/85C12N2501/60C12N2501/603C12N2501/605C12N2506/1346C12N2510/00C12N2740/15041C12N2740/16043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,428,307
App. No.
15/570,619
Granted
Oct 1, 2019
Kind
B2
Abstract

The present invention relates to a method for converting mesenchymal stem cells into endothelial cells by using specific transcription factors and, more specifically, a method for converting mesenchymal stem cells into endothelial cells by using Oct4, Nanog, Tal1, and LMO2, which are specific transcription factors. According to the present invention, the method for converting adult cells or mesenchymal stem cells, which are adult stem cells, into endothelial cells was developed by selecting two types of genes, which are less directly related to cancer induction, among cell reprogramming factors and two types of transcription factors, which are not expressed or expressed at a low level in mesenchymal stem cells, among transcription factors related to vascular development, and combining all four transcription factors. The method can be applied in the production of endothelial cells for forming regenerative tissue in tissue engineering and ischemic disease therapy.

Claims (4)

1. An in vitro method for converting mesenchymal stem cells into endothelial cells, the method comprising the steps of:

(a) introducing lentiviral vectors comprising Oct4, Nanog, Tal1, and LMO2 genes into the mesenchymal stem cells; and

(b) culturing the transduced mesenchymal stem cells on a gelatin-coated plate under culture conditions comprising endothelial cell growth medium EGM2 and SB431542, wherein said culturing induces the conversion of the mesenchymal stem cells into endothelial cells.

2. The method of claim 1 , wherein the Oct4 gene comprises SEQ ID NO: 1, the Nanog gene comprises SEQ ID NO: 2, the Tal1 gene comprises SEQ ID NO: 3, and the LMO2 gene comprises SEQ ID NO: 4.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2019
From: JOE, YOUNG-AE
To: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Reel/Frame 048256/0246 →
Priority Claims (2)
KR 10-2015-0060259 · Apr 29, 2015 · national
KR 10-2016-0053144 · Apr 29, 2016 · national
Continuity (1)
Related Publication 20190055518A1 · Feb 21, 2019